FDA Unveils Expedited IND Pilot Program to Accelerate First-in-Human Clinical Trials

The U.S. Food and Drug Administration (FDA) has rolled out a new Expedited Investigational New Drug (IND) Pilot Program designed to compress timelines for advancing novel therapeutic candidates from preclinical development into first-in-human (FIH) Phase 1 clinical studies. The initiative seeks to make early-stage drug development significantly more collaborative, agile, and predictable without lowering regulatory thresholds or safety baselines.

Collaborative Model: Qualified Research Institutions (QRIs)

A central pillar of the initiative requires pharmaceutical sponsors to submit joint applications alongside designated Qualified Research Institutions (QRIs). Eligible QRIs include academic medical centers, contract research organizations (CROs), integrated healthcare networks, and specialized scientific research bodies. These institutions will work directly with sponsors across four technical domains:

Nonclinical Assessment: Pharmacology and toxicology evaluation
Translational Strategy: Early clinical development design
CMC Oversight: Chemistry, Manufacturing, and Controls compliance
Regulatory Operations: Comprehensive IND dossier compilation and strategy

Rolling Dossier Reviews to Prevent Clinical Holds

Unlike the conventional pathway where an IND dossier is evaluated in its entirety upon submission, this pilot introduces a rolling review mechanism during the pre-IND phase. The agency will review distinct modular components as they are completed. This staged submission model allows regulators and sponsors to troubleshoot scientific, CMC, or safety ambiguities early, directly mitigating the risk of regulatory delays or clinical holds once the formal 30-day statutory review window begins.

The framework also promotes parallel track coordination, prompting sponsors and trial sites to complete Institutional Review Board (IRB) clearances and site-activation milestones concurrently with dossier evaluation.

Cohort Size and Application Deadlines

Cohort Target: The agency intends to admit approximately 8 to 10 Sponsor-QRI partnerships for the initial cohort.
Filing Window: Submissions opened on September 15, 2026, and will close on October 30, 2026.
Submission Format: Sponsors and prospective QRIs must file together via a unified application package.

Data and operational metrics generated during the pilot will inform future FDA policies regarding institutional accreditation for early-stage development support. The agency underscored that statutory review mandates and formal regulatory authorities regarding clinical trial clearance remain unaltered under the pilot.